Tyrosine Kinase Inhibitors in Pediatric Malignancies

REFERENCES

• Druker B. J., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 1996; 2: 561–6
   PubMed Web of Science ®Google Scholar
• Druker B. J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 2001; 344: 1031–7
   PubMed Web of Science ®Google Scholar
• Manning G., Whyte D. B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912–34
   PubMed Web of Science ®Google Scholar
• Buchdunger E., et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 2000; 295: 139–45
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211–25
   PubMed Web of Science ®Google Scholar
• Hubbard S. R., Till J. H. Protein tyrosine kinase structure and function. Annu. Rev. Biochem. 2000; 69: 373–98
   PubMed Web of Science ®Google Scholar
• Robinson D. R., Wu Y. M., Lin S. F. The protein tyrosine kinase family of the human genome. Oncogene 2000; 19: 5548–57
   PubMed Web of Science ®Google Scholar
• Madhusudan S., Ganesan T. S. Tyrosine kinase inhibitors in cancer therapy. Clin. Biochem. 2004; 37: 618–35
   PubMed Web of Science ®Google Scholar
• Noble M. E., Endicott J. A., Johnson L. N. Protein kinase inhibitors: insights into drug design from structure. Science 2004; 303: 1800–5
   PubMed Web of Science ®Google Scholar
• Heisterkamp N., et al. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983; 306: 239–42
   PubMed Web of Science ®Google Scholar
• Bartram C. R., et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983; 306: 277–80
   PubMed Web of Science ®Google Scholar
• Druker B. J. STI571 (Gleevec™) as a paradigm for cancer therapy. Trends in Molecular Medicine 2002; 8: S14–S17
   PubMed Web of Science ®Google Scholar
• Buchdunger E, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet derived growth factor receptors. J. Pharmacol. Exp. Ther. 2000; 295: 139–45
   PubMed Web of Science ®Google Scholar
• Deininger M. W., Goldman J. M., Lydon N., Melo J. V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90: 3691–8
   PubMed Web of Science ®Google Scholar
• Beran M., et al. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin. Cancer Res 1998; 4: 1661–72
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C., et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis. 1997; 23: 380–94
   PubMed Web of Science ®Google Scholar
• Champagne M. A., et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 2004; 104: 2655–60
   PubMed Web of Science ®Google Scholar
• Heinrich M. C., et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925–32
   PubMed Web of Science ®Google Scholar
• Kilic T., et al. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res. 2000; 60: 5143–50
   PubMed Web of Science ®Google Scholar
• Wang W. L., et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene 2000; 19: 3521–8
   PubMed Web of Science ®Google Scholar
• Krystal G. W., Honsawek S., Litz J., Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin. Cancer Res. 2000; 6: 3319–26
   PubMed Web of Science ®Google Scholar
• Blandford M. C., et al. Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: a report from the Children's Oncology Group. Pediatr. Blood Cancer 2006; 46: 329–38
   PubMed Web of Science ®Google Scholar
• Oda Y., et al. Expression of growth factors and their receptors in human osteosarcomas. Immunohistochemical detection of epidermal growth factor, platelet-derived growth factor and their receptors: its correlation with proliferating activities and p53 expression. Gen. Diagn. Pathol. 1995; 141: 97–103
   Google Scholar
• Zhang P. J., et al. PDGF-A, PDGF-Rbeta, TGFbeta3 and bone morphogenic protein-4 in desmoplastic small round cell tumors with EWS-WT1 gene fusion product and their role in stromal desmoplasia: an immunohistochemical study. Mod. Pathol. 2005; 18: 382–7
   PubMed Web of Science ®Google Scholar
• Tamborini E., et al. Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma. Clin. Cancer Res. 2004; 10: 938–43
   PubMed Web of Science ®Google Scholar
• Chilton-Macneill S., et al. C-kit expression and mutational analysis in medulloblastoma. Pediatr. Dev. Pathol. 2004; 7: 493–8
   PubMed Web of Science ®Google Scholar
• Smithey B. E., Pappo A. S., Hill D. A. C-kit expression in pediatric solid tumors: a comparative immunohistochemical study. Am. J. Surg. Pathol. 2002; 26: 486–92
   PubMed Web of Science ®Google Scholar
• Bond M., et al. Phase 2 trial of Imatinib mesylate (IM) for treatment of recurrent or refractory pediatric solid tumors; A Children's Oncology Group Study. Journal of Clinical Oncology 2005; 23: 8520
   PubMedGoogle Scholar
• Kuroiwa M., et al. Advanced-stage gastrointestinal stromal tumor treated with imatinib in a 12-year-old girl with a unique mutation of PDGFRA. J. Pediatr. Surg. 2005; 40: 1798–801
   PubMed Web of Science ®Google Scholar
• Miettinen M., Lasota J., Sobin L. H. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am. J. Surg. Pathol. 2005; 29: 1373–81
   PubMed Web of Science ®Google Scholar
• Salomon D. S., Brandt R., Ciardiello F. N., Epidermal N. Growth factor peptides and their receptors in human malignancies. Critical Reviews in Oncology and Hematology 1995; 19: 183–232
   PubMed Web of Science ®Google Scholar
• Meyers M. B., et al. Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells. J. Cell. Biochem. 1988; 38: 87–97
   PubMed Web of Science ®Google Scholar
• Layfield L. J., Thompson J. K., Dodge R. K., Kerns B. J. Prognostic indicators for neuroblastoma: stage, grade, DNA ploidy, MIB-1-proliferation index, p53, HER-2/neu and EGFr–a survival study. J. Surg. Oncol. 1995; 59: 21–7
   PubMed Web of Science ®Google Scholar
• Zhang L., Jope R. S. Muscarinic M3 and epidermal growth factor receptors activate mutually inhibitory signaling cascades in human neuroblastoma SH-SY5Y cells. Biochem. Biophys. Res. Commun. 1999; 255: 774–7
   PubMed Web of Science ®Google Scholar
• Ghanem M. A., et al. Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma. Cancer 2001; 92: 3120–9
   PubMed Web of Science ®Google Scholar
• De Giovanni C., et al. Antisense epidermal growth factor receptor transfection impairs the proliferative ability of human rhabdomyosarcoma cells. Cancer Res. 1996; 56: 3898–901
   PubMed Web of Science ®Google Scholar
• Hughes D. P., Thomas D. G., Giordano T. J., Baker L. H., McDonagh K. T. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res. 2004; 64: 2047–53
   PubMed Web of Science ®Google Scholar
• Bredel M., Pollack I. F., Hamilton R. L., James C. D. Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin. Cancer Res. 1999; 5: 1786–92
   PubMed Web of Science ®Google Scholar
• Gilbertson R. J., Pearson A. D., Perry R. H., Jaros E., Kelly P. J. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br. J. Cancer 1995; 71: 473–7
   PubMed Web of Science ®Google Scholar
• Gilbertson R., et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br. J. Cancer 2001; 85: 705–12
   PubMed Web of Science ®Google Scholar
• Gilbertson R. J., et al. ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin. Cancer Res. 2003; 9: 3620–4
   PubMed Web of Science ®Google Scholar
• Hernan R., et al. ERBB2 up-regulates S100A4 and several other prometastatic genes in medulloblastoma. Cancer Res. 2003; 63: 140–8
   PubMed Web of Science ®Google Scholar
• Moyer J. D., et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997; 57: 4838–48
   PubMed Web of Science ®Google Scholar
• Lynch T. J., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350: 2129–39
   PubMed Web of Science ®Google Scholar
• Paez J. G., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–500
   PubMed Web of Science ®Google Scholar
• Pao W., et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 13306–11
   PubMed Web of Science ®Google Scholar
• Cappuzzo F., et al. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J. Natl. Cancer Inst. 2004; 96: 1133–41
   PubMed Web of Science ®Google Scholar
• Stewart C. F., et al. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res. 2004; 64: 7491–9
   PubMed Web of Science ®Google Scholar
• Ozvegy-Laczka C., et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 2004; 65: 1485–95
   PubMed Web of Science ®Google Scholar
• Yanase K., et al. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. Mol. Cancer Ther. 2004; 3: 1119–25
   PubMed Web of Science ®Google Scholar
• Daw N. C., et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J. Clin. Oncol. 2005; 23: 6172–80
   PubMed Web of Science ®Google Scholar
• Jimeno A., et al. Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. Pediatr Blood Cancer 2006
   Web of Science ®Google Scholar
• Jakacki R. I., et al. A pediatric phase I trial and pharmacokinetic (PK) study of erlotinib (ERL) followed by the combination of ERL with temozolomide (TMZ): A Children's Oncology Group Study. Journal of Clinical Oncology 2006; 24: 9015
   Google Scholar
• Harding J., Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 2005; 41: 107–27
   PubMed Web of Science ®Google Scholar
• Kim S., et al. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Clin. Cancer Res. 2006; 12: 600–7
   PubMed Web of Science ®Google Scholar
• Lenz H. J., et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J. Clin. Oncol. 2006; 24: 4914–21
   PubMed Web of Science ®Google Scholar
• Belda-Iniesta C., et al. Long term responses with cetuximab therapy in glioblastoma multiforme. Cancer Biol. Ther. 2006; 5: 912–4
   PubMed Web of Science ®Google Scholar
• Bourhis J., et al. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol. 2006; 24: 2866–72
   PubMed Web of Science ®Google Scholar
• Lilenbaum R. C. The evolving role of cetuximab in non-small cell lung cancer. Clin. Cancer Res. 2006; 12: 4432s–4435s
   PubMed Web of Science ®Google Scholar
• Modi S., et al. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin. Breast Cancer. 2006; 7: 270–7
   PubMed Web of Science ®Google Scholar
• Baselga J. The EGFR as a target for anticancer therapy–focus on cetuximab. Eur. J. Cancer 2001; 37: S16–22, Suppl 4
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis and its inhibitors. Important Advances in Oncology 1985; 42–62
   PubMedGoogle Scholar
• Kumar S. Angiogenesis and antiangiogenesis. Journal of the National Cancer Institute 1980; 64: 683–687
   PubMed Web of Science ®Google Scholar
• Zetter B. Angiogenesis and tumor metastasis. Annu. Rev. Med. 1998; 49: 407–424
   PubMed Web of Science ®Google Scholar
• Rak J., Filmus J, Kerbel R S. Reciprocal paracrine interactions between tumor cells and endothelial cells: the “angiogenic progression” hypothesis. European Journal of Cancer 1996; 32A: 2438–2450
   PubMed Web of Science ®Google Scholar
• Jain R. Hemodynamic and transport barriers to the treatment of solid tumors. International Journal of Radiation Biology 1991; 60: 85–100
   PubMed Web of Science ®Google Scholar
• Rowe D. H., et al. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J. Pediatr. Surg. 2000; 35: 30–2, discussion 32–3
   PubMed Web of Science ®Google Scholar
• Rowe D. H., et al. Suppression of primary tumor growth in a mouse model of human neuroblastoma. J. Pediatr. Surg. 2000; 35: 977–81
   PubMed Web of Science ®Google Scholar
• McCrudden K. W., et al. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J. Pediatr. Surg. 2003; 38: 308–14, discussion 308–14
   PubMed Web of Science ®Google Scholar
• Gerber H. P., Kowalski J., Sherman D., Eberhard D. A., Ferrara N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 2000; 60: 6253–8
   PubMed Web of Science ®Google Scholar
• Kabbinavar F., Hurwitz H., Fehrenbacher L., et al. Phase II, randomized trial comparing bvacizumab plus fluorouracil (FU)/ leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. Jounal of Clinical Oncology 2003; 21: 60–65
   PubMed Web of Science ®Google Scholar
• Benson A. B., Catalano P. J., Meropol N. J., O'Dwyer P. J., Giantonio B. J. Bevacizumab (anti-VEGF) plus FOLFOX4 in perviously treated anvanced colorectal cancer: an interim toxicity analysis of the Eastern Cooperative Oncology Group Study E3200. Proceedings of American Society of Clinical Oncology 2003; 22: 243
   Google Scholar
• Glade Bender J. L., et al. A phase I study of bevacizumab in children with refractory solid tumors: A Children's Oncology Group study. Journal of Clinical Oncology 2006; 24: 9017
   Google Scholar
• Gordon M. S., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. Jounal of Clinical Oncology 2001; 19: 843–850
   PubMed Web of Science ®Google Scholar
• Lyman S. D., Jacobsen S. E. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91: 1101–34
   PubMed Web of Science ®Google Scholar
• Brown P., Small D. FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. Eur. J. Cancer 2004; 40: 707–21, discussion 722–4
   PubMed Web of Science ®Google Scholar
• Timeus F., et al. Flt-3 and its ligand are expressed in neural crest-derived tumors and promote survival and proliferation of their cell lines. Lab. Invest. 2001; 81: 1025–37
   PubMed Web of Science ®Google Scholar
• Meshinchi S., et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001; 97: 89–94
   PubMed Web of Science ®Google Scholar
• Brown P., et al. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 2005; 105: 812–20
   PubMed Web of Science ®Google Scholar
• Smith B. D., et al. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004; 103: 3669–76
   PubMed Web of Science ®Google Scholar
• Desmet C. J., Peeper D. S. The neurotrophic receptor TrkB: a drug target in anti-cancer therapy?. Cell Mol. Life Sci. 2006; 63: 755–9
   PubMed Web of Science ®Google Scholar
• Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Let. 2001; 169: 107–14
   PubMed Web of Science ®Google Scholar
• Miknyoczki S. J., Chang H., Klein-Szanto A., Dionne C. A., Ruggeri B. A. The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma. Clin. Cancer Res. 1999; 5: 2205–12
   PubMed Web of Science ®Google Scholar
• Brodeur G. M., et al. Expression of TrkA, TrkB and TrkC in human neuroblastomas. J. Neurooncol. 1997; 31: 49–55
   PubMed Web of Science ®Google Scholar
• Evans A. E., et al. Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts. Clin. Cancer Res. 1999; 5: 3594–602
   PubMed Web of Science ®Google Scholar
• Gorre M. E., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–80
   PubMed Web of Science ®Google Scholar
• O'Farrell A. M., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597–605
   PubMed Web of Science ®Google Scholar
• Abrams T. J., Lee L. B., Murray L. J., Pryer N. K., Cherrington J. M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2003; 2: 471–8
   PubMed Web of Science ®Google Scholar
• Abrams T. J., et al. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol. Cancer Ther. 2003; 2: 1011–21
   PubMed Web of Science ®Google Scholar
• Mendel D. B., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003; 9: 327–37
   PubMed Web of Science ®Google Scholar
• Fiedler W., et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005; 105: 986–93
   PubMed Web of Science ®Google Scholar
• Motzer R. J., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2006; 24: 16–24
   PubMed Web of Science ®Google Scholar
• Davies H., et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949–54
   PubMed Web of Science ®Google Scholar
• Beeram M., Patnaik A., Rowinsky E. K. Raf: a strategic target for therapeutic development against cancer. J. Clin. Oncol. 2005; 23: 6771–90
   PubMed Web of Science ®Google Scholar
• Jain L., Venitz J., Figg W. D. Randomized Discontinuation Trial of Sorafenib (BAY 43–9006). Cancer Biol. Ther. 2006; 5
   Web of Science ®Google Scholar
• Abou-Alfa G. K., et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 2006; 24: 4293–300
   PubMed Web of Science ®Google Scholar
• Dasatinib: BMS 354825. Drugs R. D. 2006; 7: 129–32
   PubMedGoogle Scholar
• Talpaz M., et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 2006; 354: 2531–41
   PubMed Web of Science ®Google Scholar